Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877150 | 1.00 | SIGMAR1 (0.52) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL4877592 | 0.89 | SIGMAR1 (0.52) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL4877583 | 0.89 | SIGMAR1 (0.52) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL4880794 | 0.88 | SIGMAR1 (0.51) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL5771453 | 0.88 | SIGMAR1 (0.51) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL4880806 | 0.88 | SIGMAR1 (0.51) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| Hydrochloric Acid SCHEMBL4887063 | 0.87 | SIGMAR1 (0.50) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| Hydrochloric Acid SCHEMBL4887072 | 0.87 | SIGMAR1 (0.50) | SIGMAR1MCHR1KMT2ADRD4CXCR3 | |
| SCHEMBL4868269 | 0.87 | SOAT1 (0.40) | SIGMAR1KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL4868281 | 0.87 | SOAT1 (0.40) | SIGMAR1KMT2ACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | SIGMAR1 298/4885MCHR1 1709/4885KMT2A 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.